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Abstract: Members of the human Polyomaviridae family are ubiquitous and pathogenic
among immune-compromised individuals. While only Merkel cell polyomavirus (MCPyV)
has conclusively been linked to human cancer, all members of the polyomavirus
(PyV) family encode the oncoprotein T antigen and may be potentially carcinogenic.
Studies focusing on PyV pathogenesis in humans have become more abundant as the
number of PyV family members and the list of associated diseases has expanded.
BK polyomavirus (BKPyV) in particular has emerged as a new opportunistic pathogen
among HIV positive individuals, carrying harmful implications. Increasing evidence links
BKPyV to HIV-associated salivary gland disease (HIVSGD). HIVSGD is associated with
elevated risk of lymphoma formation and its prevalence has increased among HIV/AIDS
patients. Determining the relationship between BKPyV, disease and tumorigenesis among
immunosuppressed individuals is necessary and will allow for expanding effective anti-viral
treatment and prevention options in the future.
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1. Polyomavirus Family
The term polyomavirus (PyV) stems from poly- (Greek; multiple) and -oma (Greek; tumors)
and was coined when the murine PyV (MPyV) was discovered in neonatal mice with multiple
tumors in 1953 [1]. Human polyomaviruses (HPyV) are ubiquitous, opportunistic in nature, and
are a rapidly expanding viral cluster. Currently, there are 13 PyV members that infect humans
(Table 1). BK polyomavirus (BKPyV) [2], JC polyomavirus (JCPyV) [3] and the more recently
discovered Merkel cell polyomavirus (MCPyV) [4] are widely recognized etiological agents of
BKPyV-associated nephropathy (BKVN), progressive multifocal leukoencephalopathy (PML) and
Merkel cell carcinoma (MCC), respectively [5,6] (Figure 1). The HPyV species KI (KIPyV) [7] and WU
(WUPyV) [8] were isolated from the human respiratory tract and characterized in 2007. Trichodysplasia
spinulosa-associated polyomavirus (TSPyV) was discovered in skin lesions of immunosuppressed
patients with trichodysplasia spinulosa in 2010, and TSPyV is the etiological agent of trichodysplasia
spinulosa [9]. HPyV6 [10], HPyV7 [10], HPyV9 [11], and HPyV10 [12,13] were discovered between
2010 and 2012 and are currently not associated with any disease [14], despite HPyV7 recently being
detected in human thymoma samples [15]. HPyV10, MWPyV, and MXPyV are the same species but
were isolated under different circumstances and time periods [14]. Wieland et al., evaluated cutaneous
PyV DNA prevalence and viral loads of HPyV6, HPyV7, HPyV9, TSPyV, and HPyV10 by real-time
PCR in HIV positive men compared to HIV negative male controls. While HPyV6, HPyV7, TSPyV,
and HPyV10 were detected more frequently among HIV positive men compared to HIV negative men
(p < 0.05) none of the viruses were linked to a particular disease state [16]. St. Louis polyomavirus
(STLPyV) was initially isolated from the fecal microbiota of a child in Malawi in 2013 and has since
been detected in fecal stool samples from specimens in the US and the Gambia [17,18]. HPyV12,
discovered in 2013, was PCR-amplified from liver tissue, as well as from colon, rectum, and feces
samples [19]. The New Jersey polyomavirus (NJPyV) is the most recently discovered HPyV and was
discovered in a muscle specimen from a pancreatic transplant patient with concurrent retinal blindness
and vasculitic myopathy [20].
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Table 1. List of currently known human polyomaviruses along with respective isolation
sources and year of discovery.
HPyV Year Source Reference
BKPyV 1971 Urine, transplant patient [2]
JCPyV 1971 Brain specimen, Hodgkin’s disease patient [3]
KIPyV 2007 Nasopharyngeal aspirate [7]
WUPyV 2007 Nasopharyngeal aspirate [8]
MCPyV 2008 Merkel cell carcinoma [4]
HPyV6 2010 Skin swab [10]
HPyV7 2010 Skin swab [10]
TSPyV 2010 Nose spicules, trichodysplasia spinulosa patient [9]
HPyV9 2011 Serum, kidney transplant patient [11]
HPyV10 2012 Stool sample, child [12,13]
STLPyV 2013 Stool sample, child [17]
HPyV12 2013 Liver tissue [19]




Figure 1. Graphic representation of the human compartments and organs affected by 
BKPyV, JCPyV, and MCPyV. 
Based on epidemiological and phylogenetic data, it has been hypothesized that HPyV co-evolved 
with their hosts, leading to high prevalence, low pathogenicity and symptom-less latency in immune 
competent settings [21]. HPyV tend to become latent post-primary infection and undergo reactivation 
among immune-compromised individuals, including HIV positive individuals, organ transplant patients, 
and individuals affected by autoimmune diseases [6,22–25]. Immunosuppressant conditions including 
pregnancy and chronic alcohol abuse are sufficient to lead to PyV reactivation [6]. The specific factors 
leading to reactivation are yet to be defined and it has not been determined whether the viruses undergo 
true latency, expressing only a subset of specific viral genes. Furthermore, it is unclear whether 
polyomavirus DNA is commonly integrated into the host genome or whether integration is a rare event 
specific to HPyV subtypes. MCPyV genome integration, for example, is associated with cancer 
progression [1,4]. The identification of factors associated with reactivation, latency and integration is of 
increasing importance as the prevalence of human polyomavirus family members and their associated 
diseases are increasing rapidly. 
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Based on epidemiological and phylogenetic data, it has been hypothesized that HPyV co-evolved
with their hosts, leading to high prevalence, low pathogenicity and symptom-less latency in immune
competent settings [21]. HPyV tend to become latent post-primary infection and undergo reactivation
among immune-compromised individuals, including HIV positive individuals, organ transplant patients,
and individuals affected by autoimmune diseases [6,22–25]. Immunosuppressant conditions including
pregnancy and chronic alcohol abuse are sufficient to lead to PyV reactivation [6]. The specific factors
leading to reactivation are yet to be defined and it has not been determined whether the viruses undergo
true latency, expressing only a subset of specific viral genes. Furthermore, it is unclear whether
polyomavirus DNA is commonly integrated into the host genome or whether integration is a rare
event specific to HPyV subtypes. MCPyV genome integration, for example, is associated with cancer
progression [1,4]. The identification of factors associated with reactivation, latency and integration is of
increasing importance as the prevalence of human polyomavirus family members and their associated
diseases are increasing rapidly.
All HPyV members are small non-enveloped viruses with a „45 nm diameter, contain a single
circular double-stranded DNA genome of „5.2 kb, and express at least five viral proteins [18]. While
the molecular makeup has only been sequence-deduced for the newly discovered HPyV, the genomes
contain two distinct transcriptional units: The early region, encoding the alternatively spliced large T
antigen (Tag) and small tag; and the late region, encoding the structural viral proteins VP1, VP2, and
VP3, that form the viral capsid [18]. The early and the late fragments are separated by a non-coding
control region (NCCR) containing a bi-directional promoter and the origin of viral DNA replication [18].
JCPyV, BKPyV, and SV40 (as well as other monkey polyomaviruses) encode for a sixth protein: the
agnoprotein [18]. The agnoprotein is a small polypeptide thought to have numerous functions, including
the regulation of viral gene expression [26]. Most importantly, all HPyV contain a potentially oncogenic
Tag variant [18]. While none of the HPyV seem to encode a middle Tag, which is present in MPyV,
alternatively spliced variants of large Tag have been characterized for different HPyV families [18]. For
example, MCPyV encodes a 57k Tag [27,28] and JCPyV encodes T’135, T’136, and T’165 [29].
2. The Oncogenic Potential of Human Polyomaviruses
The best-studied member of the PyV family, while not considered to be a human pathogen, is the
simian vacuolating virus 40 (SV40) [30]. Discovered in 1960, SV40 was one of the first DNA tumor
viruses to be described, and its discovery was closely tied to the polio vaccine development in the 1950s.
Polio vaccines, along with other viral vaccines, were prepared in primary cell cultures of rhesus monkey
kidney cells, some of which contained SV40 [31]. Soon after, SV40 was revealed to induce salivary
gland carcinomas in murine neonates [32] and mesotheliomas, lymphomas, brain tumors, bone tumors,
and sarcomas in hamsters [33]. In human biopsies, tumors equivalent to the hamster types have been
found to contain SV40 DNA and proteins, which is why mesotheliomas and brain tumors have been most
consistently linked with SV40 [33]. However, the range of SV40 disease associations has varied from 0
to 100% [33]. While SV40 may be a co-factor in human carcinogenesis, it appears unlikely that SV40
infection alone is sufficient to cause human malignancy as definite links to cancer-formation have not
been detected in humans and no cancer epidemics were observed following the administration of polio
and adenovirus vaccines contaminated with SV40 [1,29].
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SV40 underwent intensive investigation immediately after the potential public health risk posed by
the distribution of SV40 contaminated vaccines [31] and the subsequent findings became central to both
molecular and cancer biology [34,35]. Thanks to SV40, transcriptional regulation enhancers, alternative
splicing, eukaryotic chromosomal DNA replication characterization, identification of tumor suppressor
protein p53, elucidation of viral effects on cell cycle regulation, and identification of a protein nuclear
localization signal was achieved [31]. Moreover, the extensive studies focusing on SV40 identified the
two major viral oncoproteins, large Tag (90–100 kDa nuclear protein) and small tag (17–22 kDa), which
are present in all human polyomaviruses (HPyV) [34]. SV40 achieves cellular transformation by using
Tag to bypass vital cellular checkpoints. The host cell is forced into the cell cycle S phase, bypassing
apoptosis by inactivating the tumor suppressor p53 via Tag binding (inactivating functional activity of
p53) [34,35]. RB and other small pocket protein family members, p107 and p130, also bind to large Tag
that prevents interaction with E2F1 (a transcription factor responsible for controlled expression of cell
cycle-promoting gene), causing the loss of suppression [34,36]. Thus, Tag binding p53 and pRb leads to
highly proliferative and uncontrolled cell growth. Studies have shown that Tag interacts with other host
proteins, including hsc70, CBP/p300, Cul7 IRS1, Fbxw7, Bub1 and transcription factors including AP-1,
AP-2, Sp1, TEF-1, TBP, TAF1 (TAFII250), TAF4 (TAFII135), and TAF5 (TAFII100) [34,37]. Small tag
is considered to be an oncogenic enhancer and interacts with the tumor suppressor serine-threonine
protein phosphatase 2A (PP2A), which mediates transformation-enhancing signaling pathways [34,37].
Together Tag and tag complete the tumorigenic potential for SV40 and potentially for all HPyVs [34,37].
The oncoprotein Tag is thought to drive transformation of BKPyV laboratory infection in rodents
(neonate hamsters, rats and mice) and in vitro, inducing tumorigenesis or transformation [38–40].
Furthermore, transgenic models established the oncogenic role of MCPyV and JCPyV Tag and
tag [41–43]. Transgenic mice encoding for MCPyV tag displayed the robust malignant transformation
ability of tag, as tag-expressing embryos exhibited hyperplasia, impaired differentiation, increased
proliferation, apoptosis, and the activation of a DNA damage response [41]. Interestingly, the epithelial
transformation process did not depend on the tag-PP2A interaction, but was strictly linked to a recently
described Fbxw7 domain [41]. Another murine model, expressing small and large MCPyV T antigens,
displayed hyperplasia, hyperkeratosis, and acanthosis of the skin with additional abnormalities in
whisker pads, footpads, and eyes [42]. Additionally, neoplastic progression within stratified epithelia
was evident with increased cellular proliferation, unscheduled DNA synthesis, increased E2F-responsive
gene levels, disrupted differentiation, and the presence of a DNA damage response [42]. As for
JCPyV, infection of primary hamster brain cells generated rapidly growing cells that exhibited numerous
characteristics of a transformed phenotype, such as growth in low serum, enhanced production
of plasminogen activator, and anchorage-independent growth [43–45]. JCPyV infection in Syrian
hamster brains in vivo led to tumors that included medulloblastomas, primitive neuroectodermal tumors,
astrocytomas, glioblastoma multiforme, and peripheral neuroblastomas [43,46–48].
The “hit and run hypothesis” is a mechanism deemed valid to justify a co-factorial role of HPyV
(other than MCPyV) in cancer onset and progression in humans [31,49]. The hypothesis suggests HPyV
causing the host cell cycle to reach the critical point of no return during oncogenic transformation without
completing the full viral life cycle [49]. Hence, Tag gene expression, leading to inactivation of p53,
without evidence of a productive infection (i.e., viral protein expression, genome replication, etc.), leads
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to host cell transformation [49]. Causality based on this theory is hard to prove experimentally since the
complete disappearance of the virus in tumor cells is likely, as HPyV Tag paves the way for tumorigenic
transformation without the host cell actually supporting a full viral life cycle [49].
A possible auxiliary role of HPyV in cancer was suggested based on the following premises: (i)
Viral oncoproteins transactivate promoters of other oncoviruses present in the host cell, upregulating
the oncogene expression of the superinfecting virus, which in turn would enhance the neoplastic
development of the host cell; (ii) Oncoviruses are known to evade the innate immune system
efficiently, such as by down-regulating TLR expression, and could enhance the likelihood of a
superinfection with other oncoviruses [14]. Hence, HPyV may synergize with other viruses in oncogenic
transformation [14].
Furthermore, PyV infection poses a unique genotoxic threat to the host cell by inducing a DNA
damage response [50]. DNA damage induces a potent cellular DNA damage response (DDR) to maintain
genomic integrity [50]. The two protein kinases, ATM (ataxia telangiectasia mutated) and ATR (ataxia
telangiectasia and Rad3 related), are major regulators of DNA damage recognition and repair and recent
investigation proposes that these essential DDR proteins are required for productive PyV infection [50].
The induced DNA damage responses on the other hand may affect host genomic stability and be an
additional oncogenic driver [50].
MCPyV, isolated from Merkel cell carcinoma (MCC) in 2008 [4], is the only recognized HPyV to
cause cancer [1,4,51]. MCPyV, a 2A carcinogen (probably carcinogenic to humans), is the etiological
agent of MCC [51]. MCC incidence increases with increased age, immunodeficiency, and sun
exposure [51,52]. MCPyV is detected in the majority of analyzed MCC biopsies [1,51], but MCC
tumor cells do not produce detectable viral particles [53,54] consistent with integration of the viral
genome. PCR-amplified MCPyV DNA has frequently been reported among non-melanoma skin cancers
of immunosuppressed patients, such as squamous cell carcinoma, basal cell carcinoma and Bowens
Disease [1,55]. The specific link between MCPyV and MCC was solidified by studies published between
2008 and 2012. Initially, MCPyV DNA presence was investigated in 5 MCC patients and 10 small
cell lung carcinoma (SCLC) patients (both being small neuroendocrine carcinomas), where 40% of
MCC specimens but no SCLC specimens were MCPyV positive [1,56]. MCPyV DNA presence was
subsequently investigated in 25 pediatric brain tumors, 30 lung tumors, 28 prostate tumors [36,57],
and dried blood spot samples of children who later developed leukemia [1,58]. None of these samples
were MCPyV DNA positive. Finally, in a more extensive study of 1241 tumors, 10 MCC biopsies that
were PCR-amplified were found to be MCPyV DNA positive, but none of the other cancers analyzed
(melanoma, basal cell carcinoma, uterine cervix, uterine cervix, large bowel, ovary, breast, bone, and
soft tissue) were positive for MCPyV DNA [59]. Thus, MCPyV was confirmed as the etiologic agent of
MCC but of no other cancer.
MCPyV genomes are clonally integrated in approximately 85% of all MCC cases and all recuperated
integrated genomes and MCC cell lines carry the same signature mutations in the early gene transcripts
encoding for Tag [28]. These mutations are important because they selectively abolish viral replication
but maintain the oncogene Rb-binding ability, suggesting that the Rb fragment found within the viral
protein Tag plays a crucial role during MCC pathogenesis [28]. Similar mutations that potentially lead to
oncogenesis may be identified among other HPyVs in the future. While in vitro systems allow the study
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of viral replication post-transfection [28], MCPyV serial transmission has not been possible. The specific
human cell type or tissue supporting MCPyV virion production has not yet been identified. However,
UV irradiation induces increased MCPyV small Tag transcription in vivo, which may rationalize the
association between sun exposure, MCPyV infection, and MCC incidence [51,60].
Interestingly, a study testing the presence of MCPyV Tag in 58 samples from diverse CNS
malignancies by quantitative real-time PCR found 34 (58.6%) positives, of which 19.0% were
schwannomas, 13.8% were meningiomas and 5.2% were pituitary adenomas [61]. While the difference
between MCPyV positivity in different types of CNS malignancies was not statistically significant
(p = 0.066), a multiple linear regression analysis revealed statistically significant differences in MCPyV
copy number between meningioma and other CNS tumor types, when the model was adjusted for age
and sex (p = 0.024) [61]. Hence, the study adds evidence of MCPyV Tag sequence detection among
human CNS tumors, despite the numbers being low.
Among the known HPyV members (other than MCPyV), only BKPyV and JCPyV are accredited
to be likely to cause human cancers and are classified as 2B carcinogens (possibly carcinogenic to
humans) (Figure 1). Clearly, extensive research is required to elucidate the molecular mechanisms
underlying viral oncogenic activity and confirm a virus as the etiological agent [49]. While none of
the recent studies conclusively corroborate this association (except for MCPyV), evidence continues
to accumulate. For example, the JCPyV, which linked to leukoencephalopathy (PML) among patients
with suppressed immune systems (most of whom have either hematologic malignancies (13%) [62],
receive immunosuppressive therapy (7%) [63] or are diagnosed with AIDS (80%) [29,62,64,65]) is
possibly involved in the pathogenesis of colorectal cancer (CRC) [65,66]. CRC is the third most
common cancer in females and the fourth most common cancer in males and caused over 694,000
deaths in 2012 alone [67]. JCPyV infects and transforms in vitro cultures and induced tumors in
laboratory animal models [66,68]. Data suggests that in an infected human colon, partial JCPyV DNA
integration, along with additional events may lead to tumorigenesis and cancer progression [66]. The
oncogenic potential of JCPyV may be mediated by the PyV oncogene Tag and tissue-specific JCPyV
tropism. Tissues supporting permissive JCPyV replication may be lysed, such as oligodendrocytes,
whereas cells lacking this tolerance (for example colorectal epithelial cells) may undergo malignant
cell transformation [65,69]. Interestingly, JCPyV DNA has been detected in various neoplastic lesions
such as oligodendroglioma, astrocytoma medulloblastoma, ependymoma, glioblastoma as well as
colorectal carcinoma, gastrointestinal and anal cancers [29,65] (Figure 1), despite the lack of confirmed
JCPyV-mediated etiology.
Rennspiess et al., recently detected HPyV7-specific nuclear hybridization signals within the
neoplastic epithelial cells of 23 thymomas (62.2%) [15]. Of the 20 hyperplastic thymi analyzed, 40%
were HPyV7-positive by PCR and confirmed by FISH and IHC in the follicular lymphocytes, whereas all
20 fetal thymi tested HPyV7-negative [15]. The presence of HPyV7-DNA and large Tag expression in the
majority of thymomas may link HPyV7 to humanthymomagenesis [15]. However, further investigations
are needed to confirm the association between HPyV7 and human thymomas.
A causal relationship was proposed between BKPyV reactivation and the development of bladder
cancer in renal transplant patients based on elevated urine BKPyV VLs and the presence of BKPyV
DNA in bladder cancer biopsies [70]. The study described a patient that had persistent elevated BKPyV
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viruria after renal transplantation with subsequent bladder cancer formation (13 months post-kidney
transplantation) and dramatic urine BKPyV VL drop after removal of the bladder cancer [70]. Plus,
BKPyV DNA was found in the marginal and central part of the bladder tumor [70].
Likewise, there is data suggesting BKPyV to be the etiological agent of prostate cancer. Prostate
cancer is a common tumor in Western countries and abrogated p53 function is thought to contribute to
prostate cancer risk [71]. BKPyV may contribute to prostate cancer development by Tag-mediated p53
interactions [71]. Indeed a quantitative PCR-based study searching for BKPyV viral DNA among clinical
prostate cancer samples found that viral DNA copy numbers were higher in cancer tissues taken from
higher Gleason score patients as compared to patients with lower Gleason scores [71]. Furthermore,
different p53 mutations were found according to tumor-advanced stages and a statistical significant
correlation was found between Gleason score and p53 mutational rate [71]. Most recently, in the cancer
genome atlas study TCGA, abundant BKPyV was detected in a bladder cancer with associated high
levels of Tag expression [72].
Das et al., detected BKPyV DNA in the epithelial cells of benign and proliferative inflammatory
atrophy ducts of cancerous prostate specimens [73]. Another study from the same group showed that
BKPyV was present at a much lower frequency in noncancerous prostates [74]. In healthy prostates, Tag
expression was observed only in specimens harboring proliferative inflammatory atrophy and prostatic
intraepithelial neoplasia [74]. The study further showed that the p53 gene from atrophic cells expressing
Tag were wild type, whereas tumor cells expressing detectable nuclear p53 contain a mix of wild-type
and mutant p53 genes, suggesting that Tag may inactivate p53 in the atrophic cells [74].
Several studies have suggested BKPyV to be oral-tropic [75–78] and recently the question whether
BKPyV and JCPyV play a role in oral squamous cell carcinoma was posed [79]. Head and neck cancers
are the most common cancers worldwide and is estimated that approximately 90% of all head and neck
cancers are squamous cell carcinomas [79]. Infectious agents, such as viruses are one of many risk
factors [79]. Polz et al., analyzed the correlation between BKPyV infection and oral squamous cell
carcinomas, while accounting for alcohol abuse, tobacco smoking, demographic data, pre-treatment
staging, metastases of lymph node evidence, and grading [79]. The study included 92 patients diagnosed
with oral squamous cell carcinoma and the results determined that BKPyV DNA was statistically
more frequently detected among patients with squamous carcinoma as compared to the control group
(p < 0.05) [79]. Thus, BKPyV DNA was detected in 18.5% of patients with oral squamous cell
carcinoma but only in 3.3% of the controls [79]. JCPyV DNA has been detected in human tonsil tissue,
providing evidence as site of infection [80,81] but there is no evidence connecting JCPyV to squamous
cell carcinomas [79]. Importantly, a study evaluating the presence of SV40, BKPyV and JCPyV DNA
among oral squamous cell carcinoma specimens did not find a significant difference between the cases
and the controls, contraindicating a major role of any of these PyV in the etiology of oral squamous cell
carcinoma [82].
3. BK Polyomavirus (BKPyV)
BKPyV was initially isolated from the urine of a renal transplant patient in 1971 [2] and named
after the patient’s initials. BKPyV, as most members of the HPyV family, is holoendemic and found
at high frequencies throughout most human populations [21]. BKPyV transmission is still undefined
Cancers 2015, 7 1252
but may include the following courses: respiratory route during infancy [83] fecal-oral route [21],
urino-oral route [6], or via vertical transmission [84]. While primary BKPyV infection commonly occurs
without symptoms, in rare cases it can cause clinical complications such as urinary tract disease [85].
Upon reactivation BKPyV is mainly associated with three major clinical syndromes: ureteral stenosis,
hemorrhagic cystitis and BKPyV-associated nephropathy (BKVN) [86].
BKPyV consists of a naked icosahedral virion with a diameter of about 45 nm and is morphologically
indistinguishable from other HPyV [29,87]. The capsid is constituted of 72 capsomers, made of the
major structural protein VP1 and one copy of a minor structural protein VP2 or VP3, which also links
the genome to the capsid structure [88]. The viral genome is a circular, double-stranded „5kb DNA
molecule and is divided into three functional regions (Figure 2): the early region; the late region; and
the promoter, termed NCCR. The BKPyV NCCR promoter region is of bidirectional nature, consists
of five block sequences, controls transcription of the early and late genes and has been found to be the
major determinant of in vitro replication [89,90]. The O block contains 142 bp, the P block 68 bp, the
Q block 39 bp, the R block 63 bp and the S block 63 bp. The O block contains the origin of DNA
replication and each block carries a combination of transcription factor binding sites (TFBS) [78,87].
TFBS AP-1, CREB, NF-1, C/EBP, NFAT, NFκB, p53, Sp1, and Tag, among others, have been described
within the BKPyV NCCR [90–96]. The early region encodes the Tag regulatory proteins: large Tag (80.5
kDa), small tag (20.5 kDa) and the truncated Tag (17 kDa), which arise from three different mRNAs by
alternative splicing of a single primary transcript [88].
Polyomaviruses in general depend on the host cell for replication, as they do not encode for their
own polymerase. As discussed above, BKPyV Tag in particular carries numerous and indispensible
functions and displays 76% sequence similarity to the well-studied SV40 Tag [97]. Tag acts as major
regulatory protein and interacts with pRb and p53 through its domains in order to overcome the host cell
cycle control and disrupt host apoptosis (see above for more details). Furthermore, Tag carries DNA
unwinding/helicase activity and regulates viral DNA replication and gene expression by interacting with
host-cell transcription factors and the viral promoter region (NCCR) [21]. The late region encodes the
three structural proteins VP1 (40.1 kDa), VP2 (38.3 kDa), and VP3 (26.7 kDa), and the non-structural
agnoprotein (7.4 kDa). Proteins VP2 and VP3 are translated from the same transcript and the agnoprotein
and protein VP1 are translated from a different open reading frame (ORF) [88]. The agnoprotein is a
small, non-immunogenic lipid-associated cytoplasmic protein with an elusive functional nature even
though it has been thought to be important for gene expression, capsid assembly and egress [26]. The
late BKPyV genome region contains additional ORFs, which are not well studied, but may encode a
protein similar to the SV40 VP4 protein [98].
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5. HIV-Associated Salivary Gland Disease (HIVSGD)
HIV-associated salivary gland disease (HIVSGD) is currently the most common salivary gland
presentation in HIV positive individuals [103]. Incidence is as high as 48% among HIV-infected patients
in developing countries [104] and it is more commonly diagnosed among the pediatric population, while
being considered AIDS-defining among children. Importantly, HIVSGD is considered a pre-malignant
lesion and its diagnosis is associated with increased lymphoma incidence [76,105–107]. Schiodt
et al., define HIVSGD as a disease which encompasses symptoms linked to AIDS-related salivary
lymphadenopathy such as enlargement of the major salivary glands and/or xerostomia (dry mouth)
and localized lymphocytic infiltration [108]. HIVSGD presents itself superficially as unilateral or
bilateral salivary gland enlargement due to parotitis. Histologically, the oral disease is characterized
by hyperplastic, intraparotid lymph nodes and/or lymphatic CD8 + infiltrates [103]. Parotid gland
enlargements are greater and more disfiguring in children than in adults [76]. HIVSGD also affects the
minor salivary glands, with labial salivary glands demonstrating features of sialadenitis [76]. Patients
diagnosed with HIVSGD commonly have reduced salivary flow rates of the parotid, submandibular,
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and sublingual glands [103]. Saliva composition may be affected and may contain increased sodium,
chloride, lysozyme, peroxidase, lactoferrin, and immunoglobulin A levels [103].
Salivary gland disease impacts oral health, and maintenance of good oral health among
HIV/AIDS patients is of outmost importance to protect the patients from secondary and opportunistic
infections [109]. Bacterial, viral and fungal infections that begin in the mouth may escalate to systemic
infections and may in turn harm vital organs if left untreated [109]. Moreover, the decline of oral health
has been shown to impact the patient’s quality of life by limiting career opportunities and social contact
as a result of facial appearance and odor [109]. Poor oral health may also lead to complications with
food intake, leading to general malnutrition and malabsorption of vital medication [109]. Poor oral
health further predisposes the development of oral diseases, such as xerostomia. Xerostomia leads to
dental decay, periodontal disease and increases the patient’s likelihood of being affected by pathogenic
opportunistic infections [109].
Interestingly, there has been an increase in HIVSGD prevalence of among HIV positive patients in
the post-highly active antiretroviral therapy (HAART) era at the UNC hospitals (Figure 3) [110,111] and
was detected at a rate of 8% in the UNC hospital cohort in 2010. Taking a combination of three or more
anti-retroviral drugs is termed HAART and its application dramatically increases the life expectancy of
HIV positive individuals. HIVSGD has risen from 1.8% to 5% among HIV-infected adults from 1995
to 1999, even though the overall presence of oral lesions has decreased [110]. Patton’s data implies
that AIDS patients were experiencing a higher risk of developing HIVSGD under HAART treatment.
The group also determined that there was a change in the occurrence of oral opportunistic infections in
general from 1995/96, where the use of HIV protease inhibitor was less common, to 1999, a period of
greater protease inhibitor use, indicating the importance of understanding opportunistic pathogens [110].
HAART hinders AIDS progression by reducing HIV RNA levels and increasing CD4+ cell counts, but
it has been shown that opportunistic infectious agents can also take advantage of the newly reconstituted
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6. HIVSGD-Lymphoma Association
HIVSGD associated salivary gland enlargement may represent a consequence of cystic
lymphoepithelial lesions [76,112]. These lesions reflect a localized manifestation of persistent
generalized lymphadenopathy [112]. While HIVSGD is regarded as a benign condition, malignant
lymphoma has been described in association with some of these lesions [112]. Importantly, lymphomas
represent a significant proportion of malignancies of the major salivary glands, accounting for 1.7% to
7.7% of tumors [112]. Most HIV-related lymphomas and lymphoma-like lymphoproliferative disorders
are aggressive B-cell proliferations, where the incidence of non-Hodgkin lymphoma in HIV positive
individuals remains approximately 70 to 80 times greater than that of the general population [113].
Interestingly, the epidemiology of these neoplasms has changed with the introduction of HAART [113].
HIV-associated non-Hodgkin lymphomas now account for most AIDS-defining cancer types, despite
the overall incidence having decreased [113]. While the salivary B cell lymphoma is rather indolent
and tends to remain localized, as the disease progresses, regional lymph node involvement or other
extra-nodal site involvement may take place [114].
Early on, the lymphomas were solely linked to Epstein-Barr virus (EBV). A study observing six
cases of primary salivary gland lymphoma in HIV positive patients found that all of them were of high
histologic grade while salivary gland lymphomas unrelated to HIV were predominantly of low-grade
MALT type [115]. While the lymphomas in both categories expressed the B-cell phenotype EBV RNA
transcripts (EBER) were demonstrated in three, and EBV latent membrane protein (LMP) in two of
the six HIV-related and in none of the three HIV-unrelated lymphomas [76,115]. However, with new
findings connecting the head and neck compartment to BKPyV, one has to ask whether infectious agents
other than EBV may play co-factorial roles during oncogenesis.
7. BK Polyomavirus HIVSGD Association
Since Jeffers et al. detected significantly higher BKPyV viral loads (VLs) in the saliva of
patients diagnosed with HIVSGD as compared to HIV negative patients [75], evidence linking
BKPyV to HIVSGD has augmented. Jeffers et al. showed that the oral BKPyV VLs of HIVSGD
patients (n = 11) ranged from 101 to 104 copies/mL whereas the HIV negative control cohort
(n = 7) VLs ranged from 0 to 102 copies/mL. The higher BKPyV levels shed in an HIVSGD cohort
were confirmed two years later [76]. The study found highest BKPyV VLs in patients diagnosed
with HIVSGD (n = 11) as compared to patients who were HIV positive without HIVSGD (n = 46)
and HIV negative individuals (n = 12). Furthermore, using PCR and immunofluorescence, BKPyV
products (but not herpesviral DNA) were found in HIVSGD patient salivary gland biopsies but not in
biopsies from patients without HIVSGD [116]. Hence, BKPyV sequences were detected among most
HIVSGD throatwash (TW) samples and biopsies. Significantly lower BKPyV levels were detected
among HIVSGD negative TW samples and no BKPyV sequence were found among biopsies from
patients without HIVSGD. Therefore, based on Fredrick’s and Relman’s postulates, which integrate
modern sequence-based identification of microbial pathogens, a link between BKPyV and HIVSGD
is likely.
BKPyV has been shown to display oral tropism in vivo and in vitro. BKPyV has been detected
in tonsillar tissue from both pediatric and adult donors [83,117,118] and Jeffers et al., showed
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in 2009 that BKPyV is able to infect and reproduce in human salivary gland cells in vitro [75].
Laboratory strain BKPyV underwent entry, transcribed, translated and produced virions within human
submandibular (HSG) and parotid (HSY) salivary gland cells. It is plausible therefore that the oral
compartment represents an infectious reservoir in addition to the historically described renal/urinary
compartment [102,119]. Previous studies have shown that the replication compartments of urine and
plasma-derived BKPyV are distinct in vivo [120,121], similarly, the salivary gland may embody a
separate replication compartment in the HIVSGD setting [122]. Finally, clinical HIVSGD-derived
BKPyV isolates infect and complete their full viral life cycle and produce infectious viral progeny
in human salivary gland cells and provide evidence of preferred oral tropism, as oral-derived BKPyV
isolates replicated more efficiently in HSG cells than in kidney cells [78].
Detecting an increase in prevalence of HIVSGD among HIV positive patients in the HAART era may
further hint towards persistence of an opportunistic infectious agent as the cause of HIVSGD [123].
Twenty-five to 35% of patients undergoing HAART develop a pathological inflammatory response
termed immune reconstitution inflammatory syndrome (IRIS) to previously treated or asymptomatic
opportunistic infections. Interestingly, the majority of IRIS cases are reported within the first two months
of HAART, even though IRIS development can take up to two years [124].
Antigen-driven HIVSGD pathogenesis provides further evidence of an infectious agent being the
etiological agent of HIVSGD. A prospective study analyzing epidemiology, clinical presentation,
and extra-glandular manifestations of HIVSGD suggests that this lymphadenopathy is an antigen
(viral)-driven response [125]. Additionally, an antigen-driven MHC-determined host immune response
recorded by Itescu et al., based on the infiltrating lymphoid cells characterizing HIVSGD, points to an
antigen-driven response [126]. Finding differential rates of HIVSGD in children (20%–47%) and adults
(3%–7.8%) [107] may also allude to a viral infection as it indicates primary viral infection in children
versus residual immunity in adults [76]. However, future trials will have to address these questions
more specifically.
8. Potential Factors Allowing for BKPyV Tropism in the Head and Neck
Members of the polyomavirus family have a narrow species host range but infect a wide range of
cell types within a host [86], yet it is not clear which factors determine BKPyV tropism. BKPyV
capsid proteins interact directly with the receptor molecules as infection is initiated, since it is a
non-enveloped virus. This interaction is generally thought to be the major determinant of viral host and
tissue tropism [127]. BKPyV binds to cellular receptors such as N-linked glycoproteins with a 2,3-linked
sialic acids and gangliosides GD1b and GT1b. This is true for kidney (Vero) cells and oral (HSG) cells
in vitro [75]. BKPyV is subsequently internalized via caveolae-mediated endocytosis, and is transported
towards the endoplasmic reticulum (ER) via the host cell cytoskeleton. Mutations in the major capsid
protein VP1 may lead to differential host cell receptor binding. Neu et al. [128] described the structural
requirements that underlie receptor switching and showed that the amino acid at position 68 in VP1 is
a determinant of receptor specificity. The in vitro experiments show that a lysine to serine mutation of
this residue switches the receptor specificity of BKPyV from GD3 to GM1. These findings emphasize
the plasticity of viral receptor binding sites and potential host cell type retargeting mechanism. During
infection, BKPyV undergoes uncoating once at the endoplasmic reticulum (ER), and nuclear localization
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signals (found on the minor capsid proteins VP2 and/or VP3) further direct viral genomes to the nucleus
and are subsequently imported via the host’s nuclear import machinery [88]. Maraldi et al., showed that
this process is completed within 12 hours [129]. Once in the nucleus, the early genes are expressed
and the BKPyV genome is replicated before late gene expression starts and virions are assembled in
the nucleus [21]. Given that receptor interactions may not be the only factors determining tropism,
JCPyV tropism may be determined by its promoter [90,127]. It is important to consider the contribution
of transactivating factors (regulating BKPyV gene expression) to tropism [90,127]. There is evidence
that downstream events, such as endocytosis, virus-induced signaling, intracellular trafficking and
transcriptional regulation contributes significantly to viral tropism [127].
As mentioned earlier, the BKPyV NCCR promoter contains the origin of replication and the
enhancer/promoter elements of the genome and is the main determinant of BKPyV replication
in vitro [89]. The NCCR is a hypervariable region and comparative studies have suggested that it may
regulate host cell tropism mainly due to the rearrangement, duplication or deletion of TFBS [90,127,130].
It is therefore plausible that the interplay of TFBS found within the NCCR sequence of a certain BKPyV
substrain and transcription factors present within a certain cell type may allow for successful completion
of a viral life cycle and therefore determine BKPyV tropism (similar to JCPyV).
The BKPyV NCCR commonly undergoes block deletions and/or duplications as compared to
the archetype. Recently the NCCR architecture from oral-derived HIVSGD BKPyV has been
characterized and a unique OPQPQQS BKPyV NCCR promoter sequence detected among two
clinical HIVSGD-derived BKPyV isolates [78]. Promoter architectures that diverge from the original
urine-derived archetypic OPQRS arrangement are referred to as rearranged (rr) and are readily detected
in vitro and in vivo [131–139]. It has been shown that NCCR block rearrangements bestow remarkable
differences in transforming potential and host cell permissiveness [90,120,121,132,137,140]. Clinical
studies determined that the emergence of rr NCCR BKPyV variants in the plasma samples from
immune suppressed kidney transplant recipients were correlated to increased replication efficiencies and
pathogenesis [120]. Furthermore, rearranged NCCRs have been reported to be more efficient replicators
in vitro [89,90,134,141,142].
Similar to BKPyV, the JCPyV promoter has been found to rearrange, and rearrangements of following
substrains isolated from brain, kidney, lymphocytes of PML patients, brain, cerebrospinal fluids (CSF),
and lymphocytes of healthy individuals have been described [143–147]. JCPyV promoter region includes
binding sites for a variety of transcription factors, similar to the BKPyV NCCR. Interestingly, within
JCPyV it is thought that these rearrangements lead to alterations of the TFBS and hence transcriptional
patterns of the promoter, which are thought to increase the viral replication capacity in the brain and
ultimately the viral disease potential [148]. It is important to note that the correlation between promoter
structure rearrangement and disease is not perfect. The same JCPyV promoter architectures can be
found within patients with extensive disease and patients without noticeable disease [83], while it is
known that following TFBS Tst-1, NF-1, Sp1, GBPi, NFκB, YB-1, Pura, and GF-1 determine the
tropism of JCPyV to glial cells in the brain [83,149–155]. While host factors contribute to the viral
pathogenic capacity and likely fluctuate between individuals and over time [83] both JCPyV and BKPyV
promoter rearrangements are likely to drive viral replication and therefore pathogenicity in vivo. Whether
BKPyV rr NCCR variants are more efficient at in vivo disease development is debated [156,157] but not
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unlikely since JCPyV promoter rearrangements have also been suggested to drive neural tropism and
bestow increased virulence as discussed above [158]. It is important to conclusively determine whether
BKPyV promoter rearrangements truly endow higher replication levels and increased virulence in order
to understand BKPyV pathogenesis and prevent disease development effectively. This may be facilitated
by either using certain BKPyV NCCR architectures as biomarkers or treatment targets. The promoter
architecture from following samples has been described: bladder, brain, cerebrospinal fluid, eye, heart,
kidney, lung, muscle, nasopharyngeal aspirates, ovarium, monocytes, placenta, prostate, ureter, urine,
and sewage [140].
9. Conclusions
Approximately 15%–20% of cancers are thought to be caused by infectious agents [159]. Around
12% of cancers are causally linked to Epstein-Barr virus (EBV), hepatitis B virus (HBV), human
papillomavirus (HPV), human T-cell lymphotropic virus (HTLV), hepatitis C virus (HCV), Kaposi’s
sarcoma herpesvirus (KSHV), and MCPyV [159]. In the past 15 years renewed interest in HPyV
and its prevalence and pathology has been sparked as a result of novel HPyV identifications and the
accumulation of evidence suggesting that more than just the HPyV MCPyV may cause cancer. New
members of the HPyV family have been emerging as novel opportunistic pathogens among HIV/AIDS
patients and immunosuppressed individuals, possibly carrying harmful implications [99]. Additionally,
members of the HPyV family have been proposed to be co-factors for cancers induced by other
oncoviruses [14], yet there is little known about their life cycles and possible malignant transformation
potential among humans and effective antiviral treatments are rarely available. For BKPyV in particular,
there is no specific antiviral treatment available, despite BKVN often resulting in chronic allograft
dysfunction and failure [160]. Especially in the light of the newly discovered connection between
BKPyV and HIVSGD, the deleterious implications of BKPyV on public health become substantial [86].
Clearly, further elucidating the pathological process leading to HPyV- and BKPyV-associated disease and
potentially oncogenesis is critical, and the constantly improving molecular techniques for viral detection
will have to lead the way.
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